Chronic Kidney Disease

The AJMC® Chronic Kidney Disease compendium is a comprehensive resource for clinical news and expert insights on the condition and treatment of loss of kidney function.

Latest News
May 19th 2025

Childhood Cancer Survivors Face Long-Term Risk of Kidney Disease, Hypertension

May 6th 2025

High Soluble Klotho Levels Linked to Lower CKD Prevalence in Adults With Diabetes, Hypertension

April 25th 2025

SGLT2s, GLP-1s, Finerenone Have Unique Benefits in CKD, Diabetes: Meta-Analysis

April 21st 2025

Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment

April 21st 2025

Health Equity & Access Weekly Roundup: April 21, 2025

Population Health Management of Chronic Kidney Disease (CKD)

An expert panel discusses chronic kidney disease (CKD), its impact on cardiovascular disease, and the methods of treatment used on the patient populations.

Panel members
Video Series
View All
October 15th 2021

Results From the STEP Trial in China

October 15th 2021

Unmet Needs in the Management of Heart Failure

October 8th 2021

Results From the EMPEROR-Pooled Analysis

October 8th 2021

Results From EMPEROR-Preserved: CV Outcomes in Patients With HFpEF

October 1st 2021

Results From FIGARO-DKD and FIDELITY: Finerenone + SGLT2 Inhibitors

October 1st 2021

Practical Implications of the FIDELITY Pooled Analysis

September 24th 2021

Results From the FIDELITY Pooled Analysis

September 24th 2021

An Overview of the FIDELITY Pooled Analysis Design

September 17th 2021

Results From FIGARO-DKD: Finerenone’s Impact on Type 2 Diabetes and CKD

September 17th 2021

An Overview of the FIGARO-DKD Trial Design

Video Interviews
View All
April 11th 2025

New Hope for IgA Nephropathy With Atrasentan Approval: Richard Lafayette, MD, FACP

September 4th 2024

UPMC's Dr Manisha Jhamb Urges Better Kidney Disease Awareness, Integrated Care

September 13th 2023

Current Status of Chronic Kidney Disease in the US

September 13th 2023

Navigating CKD Treatment Among Comorbidities

January 22nd 2023

Dr Kirsten Johansen on Benefits of Oral Therapies for the Management of CKD

November 26th 2022

Empagliflozin Has Similar Efficacy Across Subgroups, More Data Needed in CKD: Dr Jennifer Green

October 5th 2022

Closing Thoughts on CKD Management

October 5th 2022

Continued Health Disparities Seen in Practice

September 28th 2022

Combination Therapy and Payer Perspective on CKD Therapies

September 28th 2022

Using Published Data to Consider SGLT2 Inhibitors and MRAs in CKD Management

Podcasts
View All
October 22nd 2024

Engage, Educate, Empower: Transforming Kidney Care

March 24th 2023

More Needs to Be Done to Reduce Racial Disparities in Home Dialysis

April 26th 2022

Advocating for All Patients With Chronic Kidney Disease

November 9th 2021

Managing Disparities in Chronic Kidney Disease Through Value-Based Arrangements

January 12th 2021

Examining the Shift to Value-Based Kidney Care Delivery in 2021

More News

Image credit: health care costs - Nuttapong punna
April 18th 2025

Cost-Effectiveness Analysis: CKD Screening, SGLT2 Inhibitors Can Reduce Kidney Failure Risk, Racial Disparities

Giuliana Grossi
Initiating chronic kidney disease (CKD) screening at age 55 yielded substantial reductions in kidney failure incidence and improvements in life expectancy across all groups.
Pharmacy online_evso - adobe.stock.com
April 15th 2025

SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps

Giuliana Grossi
Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Healthcare costs and fees concept.Hand of smart doctor used a calculator for medical costs in modern hospital - everythingpossible - stock.adobe.com.jpeg
April 10th 2025

National Data Show Rising Risk, Cost of CKD in Patients With Acute Myocardial Infarction

Giuliana Grossi
A series of new studies from the National Kidney Foundation Spring Clinical Meeting exhibit the association between impaired kidney function and prolonged hospital stays, higher charges, and greater resource utilization.
KidneyDisease_Fotolia_104934985_Subscription_XXL.jpg
April 8th 2025

Meta-Analysis Finds SGLT2 Inhibitors Boost Hemoglobin, Hematocrit in CKD

Giuliana Grossi
The analysis supports the integration of sodium-glucose cotransporter 2 (SGLT2) inhibitors into treatment paradigms for patients with chronic kidney disease (CKD) not only for their established benefits but also for addressing anemia.
Kidney | Image credit: Crystal light - stock.adobe.com
April 3rd 2025

FDA Approves Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy

Julia Bonavitacola
Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary immunoglobulin A (IgA) nephropathy.
The investigators concluded that epidemiological inequity in CKD and cardiovascular disease remains an important issue that requires further study of potential interventions. | Image credit: filins - stock.adobe.com
March 22nd 2025

Disparities in CKD-Associated Cardiac Arrest Across Demographics

Jared Kaltwasser
Non-Hispanic Black populations face the highest risk of death from chronic kidney disease (CKD)–associated cardiac arrest, a study found.
Naz Urooj | Image credit: Interwell Health
March 21st 2025

Contributor: Data, Education, and Community: The Winning Formula for Addressing SDOH for Kidney Care Patients

Naz Urooj, MBA Kareen Simpson, MD
Addressing patients with chronic kidney disease requires a commitment to data, education, and community, specifically in those affected by social determinants of health (SDOH).
Image Credit: selote - stock.adobe.com
March 10th 2025

New Guideline Updates to Slow CKD Progression and Reduce Cardiovascular Risk

Giuliana Grossi
The Kidney Disease: Improving Global Outcomes organization's updates to its 2024 guidelines expand SGLT2 inhibitor use and refine chronic kidney disease (CKD) management.
Doctor holding card that says furosemide | Image credit: MQ-Illustrations – stock.adobe.com
March 7th 2025

FDA Expands Furosemide Injection Label to Treat Edema in CKD

Hayden E. Klein
Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure.
Yo-Yo Dieting | Image Credit: © Karen Roach-stock.adobe.com
February 4th 2025

Weight Fluctuation Threatens Kidney Health in Type 1 Diabetes

Maggie L. Shaw
Chronic kidney disease has been linked to yo-yo dieting (also known as body-weight cycling) in the general population, which interested investigators in potential links between these weight fluctuations and increased risk of renal events among a population with type 1 diabetes.
AJMC
December 17th 2024

A Standardized Care Pathway Increases Optimal Dialysis Starts

Roy G. Marcus, MD David M. Miller, MBA Brian H. Nathanson, PhD Douglas Eckhardt, MBA Steven Henry, PharmD Katherine Kwon, MD Rohit Sharma, MD Nirav Vakharia, MD
The authors observed a significant increase in optimal starts for dialysis and in peritoneal dialysis rates after implementing a standardized end-stage renal disease transition pathway.
Park City Utah | Image Credit: © SeanPavonePhoto - stock.adobe.com
December 12th 2024

Transforming Kidney Care: Policy, Risk Stratification, and Collaborative Models

Kyle Munz
Experts at a recent Institute for Value-Based Medicine event emphasized the importance of early intervention, policy innovation, and proactive collaboration to transform the management of kidney disease and optimize patient outcomes.
kidneys and stethoscope | Image Credit: © filins - stock.adpbe.com
December 10th 2024

Dallas Nephrology Associates’ Journey to Value-Based Care

Belinda Tommey, MHA Paul Skluzacek, MD Melissa Echols, BSN LeAnn Phelps, MSN Mollyn Shew Alexander Liang, MD
Preventing or delaying the onset of end-stage kidney disease is vital. By implementing a results-driven, value-based approach, Dallas Nephrology Associates has demonstrated improved patient outcomes and value for payers.
Viet Le, PA-C, Intermountain Health
October 19th 2024

Fostering Interdisciplinary Communication: How Cardio-Renal-Metabolic Care Models Optimize Care Delivery

Kyle Munz
Viet Le, PA-C, Intermountain Health, gives insights into the benefits cardio-renal-metabolic care models provide for patients in need.
Navdeep Tangri, MD, PhD, FRCP
October 18th 2024

Population Health Strategies Are Vital for Tackling, Improving CKD Care

Kyle Munz
Navdeep Tangri, MD, PhD, FRCP, University of Manitoba, speaks to the value of population health strategies in clinical approaches to care delivery for patients with chronic kidney disease (CKD).
Value-based care calls for long-term thinking about sustained benefit | image credit: momius - stock.adobe.com
October 17th 2024

Long-Term Benefits Show the Value of Upfront Investments in Value-Based Care

Kyle Munz
Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well as the importance of thinking about the long-term benefits of value-based care.
AJMC
June 24th 2024

Identifying Chronic Kidney Disease Stage 3 With Excess Disease Burden

Austin Campbell, PhD Lihao Chu, PhD Stanley Crittenden, MD Abe Sutton, JD Adam Boehler, BS
A high-risk cohort of beneficiaries with chronic kidney disease (CKD) stage 3 have a profile similar to patients with CKD stages 4 and 5, indicating potential benefit of earlier nephrology intervention.
Kidney and stethoscope lies on a blue background | Image Credit: © filins - stock.adobe.com
June 10th 2024

Leveraging Patient Activation to Improve Kidney Health in High-Risk Patients

Shanoor N. Seervai, MPP Elizabeth Montgomery, BS Hilary Hatch, PhD Kelsey Jones Pratt, MPA Jai Seth, MSc Stella E. Sechopoulos, BA Judith H. Hibbard, DrPH
Frequency of patient-provider conversations and patient activation are the 2 most significant predictors of a high-risk patient’s behaviors to prevent kidney disease.
AJMC
May 13th 2024

Defragmentation of Care in Complex Patients With ESKD Improves Clinical Outcomes

Nathan Moore, MD David Roer, MD
A novel program utilizing an approach to defragment care for patients with end-stage kidney disease (ESKD) resulted in better patient outcomes.
FDA Approval. | Image Credit: Looker_Studio - stock.adobe.com
March 28th 2024

FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis

Cameron Santoro
The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Madeleine McDowell, MD | Image Credit: LinkedIn
October 6th 2023

Dr Madeleine McDowell: CKD Hits Harder and Earlier in Socially Challenged Neighborhoods

Giuliana Grossi
The data show the average age of dialysis in the least vulnerable neighborhoods was 68.2 years old, but 59.4 years—almost a decade earlier—in the most vulnerable.
Madeleine McDowell, MD | Image Credit: LinkedIn
October 4th 2023

Dr Madeleine McDowell Discusses How CKD Disparities, Social Challenges Impact Health Care Access

Giuliana Grossi
Madeleine McDowell, MD, hopes these data insights will help change providers' behavior in terms of adopting earlier and more regular screening for chronic kidney disease (CKD).
AJMC
September 18th 2023

Predicting Hospitalizations for Patients With Chronic Kidney Disease

Steph Karpinski, MS Scott Sibbel, PhD, MPH Kathryn Gray, MA Adam G. Walker, PhD Jiacong Luo, MD Carey Colson, MBA Juliana Stebbins, MPH Steven M. Brunelli, MD, MSCE
The authors developed an algorithm that uses medical claims to identify patients with chronic kidney disease who are at greatest risk of being hospitalized within 90 days.
[Nurse recording dialysis] Credit: iStock
September 8th 2023

Contributor: Medicare Policy Proposal Jeopardizes Care for Those on Dialysis

LaVarne A. Burton Hrant Jamgochian Lori Hartwell
CEOs of 3 kidney care organizations explain flaws in CMS' recent reimbursement proposal.
Site Logo
March 17th 2023

Have Racial Disparities in Home Dialysis Utilization Changed Over Time?

Virginia Wang, PhD Lindsay Zepel, MS Cynthia J. Coffman, PhD Clarissa J. Diamantidis, MD, MHS Sarah Hudson Scholle, DrPH, MPH Matthew L. Maciejewski, PhD
Medicare prospective payment for dialysis modestly increased availability and use of home-based dialysis treatment but did not affect historic racial disparities in home dialysis.
Site Logo
February 16th 2023

Health Care Costs Associated With Unrecognized Progression to Late-Stage Kidney Disease

Donna Spencer, PhD Stephan Dunning, MBA Jeff McPheeters, BA Jennifer St. Clair Russell, PhD, MSEd, MCHES Christopher Hane, PhD
Unrecognized disease progression is associated with higher health care costs both for patients with end-stage kidney disease and late-stage (stages G4-G5) chronic kidney disease.
Site Logo
February 14th 2023

Transition-to-Dialysis Planning, Health Care Use, and Mortality in End-Stage Renal Disease

Insiya Poonawalla, PhD, MS Kanchan Barve, MS, MBA Meghan Cockrell, MPH Amal Agarwal, DO, MBA Adrianne W. Casebeer, PhD, MS, MPP Suzanne W. Dixon, MPH, MS, RDN Yong Li, PhD
A planned transition to dialysis was associated with improved outcomes and lower mortality. These findings may inform care coordination policies for end-stage renal disease.
Black male patient.
February 7th 2023

Bloodstream Infection Risk Associated With Race, SES Among Patients on Hemodialysis

Matthew Gavidia
Data released in the CDC’s latest Morbidity and Mortality Weekly Report indicate that patients with end-stage kidney disease on hemodialysis who are Black, Hispanic/Latino, or of lower socioeconomic status (SES) are at greater risk of Staphylococcus aureus bloodstream infections, with Hispanic/Latino ethnicity cited as an independent risk factor.
white FDA logo on blue background
February 7th 2023

FDA Approves Daprodustat for Anemia From CKD in Adult Dialysis Patients

Daprodustat (Jesduvroq, GSK) is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor to gain approval in the United States.
The Top 5 CKD Articles of 2022
December 27th 2022

Top 5 Most-Read CKD Content of 2022

Julia Bonavitacola
The top 5 most-read articles about chronic kidney disease (CKD) focused on finerenone benefits, anticoagulants, dementia association, and more.
12345678
...
13>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo